These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16732709)

  • 41. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.
    Erpeldinger S; Rehman MB; Berkhout C; Pigache C; Zerbib Y; Regnault F; Guérin E; Supper I; Cornu C; Kassaï B; Gueyffier F; Boussageon R
    BMC Endocr Disord; 2016 Jul; 16(1):39. PubMed ID: 27391319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Is an intensive glycaemic control beneficial in diabetes type 2?].
    Martin S
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1940. PubMed ID: 21948602
    [No Abstract]   [Full Text] [Related]  

  • 43. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
    Dailey G
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
    Waites CR; Dominick MA; Sanderson TP; Schilling BE
    Toxicol Sci; 2007 Nov; 100(1):248-58. PubMed ID: 17675651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cardiovascular safety of antidiabetics].
    Aline Roth PW; Jornayvaz FR
    Rev Med Suisse; 2016 Jun; 12(521):1084, 1086-8. PubMed ID: 27487675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2016 Sep; 105(20):1221-1222. PubMed ID: 27705192
    [No Abstract]   [Full Text] [Related]  

  • 49. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
    Pfützner A; Weber MM; Forst T
    Expert Opin Pharmacother; 2007 Aug; 8(12):1985-98. PubMed ID: 17696799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
    Yao M; Swaminathan A; Srinivas N
    Biopharm Drug Dispos; 2007 Jan; 28(1):35-42. PubMed ID: 17117455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
    Wagenaar P
    Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
    [No Abstract]   [Full Text] [Related]  

  • 53. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 55. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M; Astrup A
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.